Live Chat

交易 BioNTech BNTX

出售
 購買

BioNTech實時圖表

5m 15m 30m 1h 4h 1d 1w

金融工具基礎知識

Weekly Search
Weekly
Daily
日期  關閉 更改 更改(%)： 開倉 高 低

最新新聞

Christine Voong 2025 Jan 17, 08:55

比特幣價格走勢突破10萬美元創新高！川普政策預期推動加密貨幣市場上漲

Christine Voong 2025 Jan 17, 07:45

黃金價格走勢持穩接近一個月高點：利率政策與川普新政成關鍵變數

Christine Voong 2025 Jan 17, 05:40

亞洲股市漲跌互見，中國經濟數據提振股市走高，日本股市因加息預期下跌

Christine Voong 2025 Jan 17, 04:50

蘋果股價下跌失去中國銷量領先地位，美股指數期貨小幅下滑

So Ze Dong 2025 Jan 16, 16:00

美股結束三連漲，蘋果領跌科技板塊，企業財報強勁但市場疲弱

Christine Voong 2025 Jan 16, 06:20

亞洲股市上漲，美國通脹數據放緩促使全球股市上揚，南韓央行維持利率不變

Christine Voong 2025 Jan 16, 04:30

原油價格走勢攀升，受美國原油庫存下降、溫和通脹數據及對俄制裁推動

Christine Voong 2025 Jan 16, 03:15

美股指數期貨小幅上揚，銀行財報強勁與通膨數據放緩提振市場信心，川普政策不確定性影響市場情緒

聯絡方式

點差

1.1513

點差(%)

1.0343 %

槓桿

1:10

隔夜利息（買入）

-0.0597 %

隔夜利息（賣出）

-0.0292 %

貨幣

USD

交易時間

市場關閉

星期二

14:31 - 20:59

星期三

14:31-20:59

星期四

14:31-20:59

星期五

14:31-20:59

分析與統計

開倉

---

上一次平倉

---

52 週高點/低點

--- – ---

市值

27033083904

流通股份

239740000

收益日期（下一個）

0000-00-00

現金殖利率 

2022-06-17

除息日

2022-06-02

遠期年股息率

0

遠期年現金殖利率

0

每股盈餘

-2

了解有關此金融工具的詳細資訊

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

相關工具

資產
出售
購買
更改(%)：

立即交易

立即交易

立即交易

立即交易
查看所有金融工具
Trustpilot
Live Chat